Exciting developments in nucleic acid based therapy and innovative research at baseclick

Dear researchers,

At baseclick, we are pushing the boundaries of nucleic acids therapeutics and making significant advances in cutting-edge research. Our focus on specific targeting and innovative delivery systems is paving the way for new treatments and therapies.?

Specific targeting

One of our most recent achievements is the collaboration with the Technical University of Munich (TUM) in using Tri-mannose for targeting of macrophage in disease lung tissue (Beck et al. 2023, Nature Communication). This let to the establishing the start-up company Rnatics GmbH, bringing this approach into clinical application. In a EU wide network, funded by the European Union (Midgest, www.mitgest.eu) we started to development targeting delivery to treat mitochondrial diseases.?

Enhancement of mRNA stability

In addition, we are advancing research to increase mRNA stability via incorporation of stabilizing non immunogenic nucleotides and modification of 5’ and 3’ ends of mRNA. Current dosing challenges in mRNA therapeutics are increased side effect of ?lipid nanoparticles (LNPs). By focusing on cellular stabilization of mRNA, we aim to increase its therapeutic efficacy and minimize potential side effects by LNPs.?This is just a small part of our efforts to improve therapeutic applications and supply products for nucleic acids-based therapeutics. Our commitment is advancing nucleic acids therapeutics and personalized medicine applications.